
    
      This study will conduct to elucidate the following clinical question;

        1. if the single urinary biomarker or the combination of urinary biomarkers will clarify
           the risk of COVID-19 confirmed mild cases. These biomarkers must be warranted to
           clinical use based on the evaluation by either CE or PMDA or FDA. Examination should be
           done within 72 h after the start of COVID-19.

        2. if above addressed biomarker can classify the effectiveness of therapy directed to
           COVID-19.
    
  